# Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

> **NCT01818596** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 252 (actual)

## Conditions studied

- HIV
- HIV Infections

## Interventions

- **DRUG:** E/C/F/TAF

## Key facts

- **NCT ID:** NCT01818596
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-27
- **Primary completion:** 2014-07-31
- **Final completion:** 2018-07-18
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01818596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01818596, "Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01818596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*